Renalytix AI Notes Verici DX's Fundraise And AIM IPO Plans

(Alliance News) - Verici DX PLC on Tuesday announced its intention to admit to training on ...

Alliance News 13 October, 2020 | 4:07PM
Email Form

(Alliance News) - Verici DX PLC on Tuesday announced its intention to admit to training on London's AIM market along with a fundraise.

The company develops clinical tests for organ transplant, which an understand how well a patient will or is responding to organ transplant - initially focus on kidney transplantation.

N+1 Singer is Verici's nominated adviser and sole bookrunner for the placing, restricted offer, and subscription - financial details of which have not been disclosed.

Renalytix AI PLC noted the announcement. In July, it proposed to distribute shares in Verici Dx Ltd - then a wholly owned subsidiary - with Renalytix shareholders becoming beneficial owners of their respective distribution shares.

Shares in Renalytix were down 1.1% at 440.00 pence in London on Tuesday.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Renalytix AI PLC 445.00 GBX 2.30 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies